Generation of tumor-specific cytotoxic T lymphocytesin vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2

1994 ◽  
Vol 38 (5) ◽  
pp. 332-338
Author(s):  
Mamoru Harada ◽  
Goro Matsuzaki ◽  
Yoshihiro Shinomiya ◽  
Shin Kurosawa ◽  
Osamu Ito ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Combined Treatment ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2

Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2

1994 ◽  
Vol 38 (5) ◽  
pp. 332-338 ◽  
Author(s):  
Mamoru Harada ◽  
Goro Matsuzaki ◽  
Yoshihiro Shinomiya ◽  
Shin Kurosawa ◽  
Osamu Ito ◽  
...  
Keyword(s):  
T Lymphocytes ◽  
Tumor Cells ◽  
Cytotoxic T Lymphocytes ◽  
Combined Treatment ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2

Specific cytotoxic activity of T lymphocyte clones derived from a patient with gliosarcoma

1988 ◽  
Vol 69 (5) ◽  
pp. 751-759 ◽  
Author(s):  
Shin-Ichi Miyatake ◽  
Haruhiko Kikuchi ◽  
Kohichi Iwasaki ◽  
Junkoh Yamashita ◽  
Yuzirou Namba ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Cytotoxic Activity ◽  
Tumor Cells ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Interleukin 2 ◽  
Target Cells ◽  
Autologous Tumor ◽  
Lymphokine Activated Killer Cells ◽  
Recombinant Interleukin 2

✓ Eleven lymphocyte clones were established from the peripheral blood lymphocytes of a patient with gliosarcoma by means of autologous tumor stimulation and the limiting-dilution technique with recombinant interleukin-2. Ten of the 11 clones were cytotoxic against the autologous tumor cell line GI-1. Seven of the 10 clones were also cytotoxic against allogeneic brain-tumor lines and HeLa cells, one clone was cytotoxic against several target cells, and two clones were specifically cytotoxic against GI-1 and allogeneic brain-tumor cells. One of the 11 clones was not cytotoxic against any target cells tested. Lymphokine-activated killer cells induced by recombinant interleukin-2 alone exhibited cytotoxic activity against all target tumor cells tested. Surface phenotypic analysis revealed that all lymphocyte clones expressed CD3 antigen, some expressed CD4 antigen, and others expressed CD8 antigen. These clones seemed to be antigen-specific cytotoxic T lymphocyte clones. Analysis with these antigen-specific cytotoxic T lymphocyte clones may be useful in the elucidation of tumor-specific or tumor-associated antigens on autologous tumor cells.

Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells

1990 ◽  
Vol 128 (2) ◽  
pp. 516-527 ◽  
Author(s):  
Saburo Yamamoto ◽  
Dave S.B. Hoon ◽  
Peter Chandler ◽  
Ingrid Schmid ◽  
Reiko F. Irie
Keyword(s):  
Tumor Cells ◽  
Low Dose ◽  
Killer Cell ◽  
Interleukin 2 ◽  
Cell Activity ◽  
Lymphokine Activated Killer Cell ◽  
Killer Cell Activity ◽  
Recombinant Interleukin 2

scholarly journals The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors.

1988 ◽  
Vol 168 (1) ◽  
pp. 47-54 ◽  
Author(s):  
A Nagler ◽  
P L Greenberg ◽  
L L Lanier ◽  
J H Phillips
Keyword(s):  
Nk Cells ◽  
Tumor Cells ◽  
Peripheral Blood ◽  
Interleukin 2 ◽  
Residual Tumor ◽  
Myelogenous Leukemia ◽  
Hematopoietic Reconstitution ◽  
Recombinant Interleukin 2 ◽  
Acute Myelogenous

In the present study, we demonstrate that resting and rIL-2-activated NK cells had no inhibitory effects on peripheral blood-derived hematopoietic progenitor (HP) cells. Peripheral blood HP cells were similar to bone marrow progenitors in phenotype and clonogenic colony formation capabilities. Peripheral blood HP cells could be cocultured in vitro with rIL-2-activated autologous NK cells for 3 d without adverse effects on the HP cells. Acute myelogenous leukemia patients in stable remission were shown to have normal percentages of NK cells and elevated percentages of peripheral blood HP cells. NK cells from most of these patients could be activated with rIL-2 to lyse fresh uncultured tumor cells as well as autologous leukemia cells without effecting the peripheral blood HP cells. These results suggest that rIL-2-activated NK cells may be used to purge peripheral blood HP cell preparations of residual tumor cells before hematopoietic reconstitution.

Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer

2013 ◽  
Vol 40 (12) ◽  
pp. 6579-6585 ◽  
Author(s):  
Cong-Jun Wang ◽  
Chao Wang ◽  
Jiang Han ◽  
Yong-Kun Wang ◽  
Lin Tang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Combined Treatment ◽  
Interleukin 2 ◽  
Recombinant Interleukin 2

Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2

1991 ◽  
Vol 33 (3) ◽  
pp. 139-145 ◽  
Author(s):  
Tadahiro Fukiage ◽  
Hiroki Murakami ◽  
Masao Eura ◽  
Tsutomu Ikawa ◽  
Takeru Ishikawa
Keyword(s):  
Tumor Cells ◽  
Interleukin 2 ◽  
Killer Cells ◽  
Allogeneic Tumor ◽  
Recombinant Interleukin 2

LOCAL HYPERTHERMIA IN TREATMENT FOR MALIGNANT BRAIN TUMORS

2018 ◽  
Vol 64 (1) ◽  
pp. 54-61
Author(s):  
A. Ryabova ◽  
O. Gribova ◽  
V. Novikov ◽  
E. Choinzonov ◽  
Zh. Starceva ◽  
...  
Keyword(s):  
Experimental Data ◽  
Radiation Therapy ◽  
Brain Tumors ◽  
Tumor Cells ◽  
Combined Treatment ◽  
Complex Treatment ◽  
Local Hyperthermia ◽  
Malignant Brain Tumors ◽  
Sensitizing Effect ◽  
Methods Of Treatment

Unsatisfactory results of complex treatment for malignant brain tumors stimulate search of new effective methods of treatment. Radiation therapy is an integral part of the combined treatment but often does not influence lethally on resistant tumor cells. Thereby in recent decades there has been an active search for different modifiers, which can increase the sensitivity of tumors to chemotherapy and radiotherapy. One of the universal sensitizers is the local hyperthermia. Experimental data showed that the effect of high temperatures had both a direct damaging effect on tumor cells and a sensitizing effect. The literature review given in the article provides an overview of the existing methods of the local hyperthermia for brain tumors treatment.

scholarly journals Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1816
Author(s):  
Jessica Amarù ◽  
Federica Barbieri ◽  
Marica Arvigo ◽  
Agnese Solari ◽  
Adriana Bajetto ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Tumor Cells ◽  
Intracellular Signaling ◽  
Somatostatin Receptor ◽  
Combined Treatment ◽  
Primary Cultures ◽  
Receptor Subtype ◽  
Camp Accumulation ◽  
Gh Secretion ◽  
Somatostatin Receptor Ligands

First-generation somatostatin receptor ligands (fg-SRLs), such as octreotide (OCT), represent the first-line medical therapy in acromegaly. Fg-SRLs show a preferential binding affinity for somatostatin receptor subtype-2 (SST2), while the second-generation ligand, pasireotide (PAS), has high affinity for multiple SSTs (SST5 > SST2 > SST3 > SST1). Whether PAS acts via SST2 in somatotroph tumors, or through other SSTs (e.g., SST5), is a matter of debate. In this light, the combined treatment OCT+PAS could result in additive/synergistic effects. We evaluated the efficacy of OCT and PAS (alone and in combination) on growth hormone (GH) secretion in primary cultures from human somatotroph tumors, as well as on cell proliferation, intracellular signaling and receptor trafficking in the rat GH4C1 cell line. The results confirmed the superimposable efficacy of OCT and PAS in reducing GH secretion (primary cultures), cell proliferation, cAMP accumulation and intracellular [Ca2+] increase (GH4C1 cells), without any additive effect observed for OCT+PAS. In GH4C1 cells, co-incubation with a SST2-selective antagonist reversed the inhibitory effect of OCT and PAS on cell proliferation and cAMP accumulation, while both compounds resulted in a robust internalization of SST2 (but not SST5). In conclusion, OCT and PAS seem to act mainly through SST2 in somatotroph tumor cells in vitro, without inducing any additive/synergistic effect when tested in combination.

Sign in / Sign up

Export Citation Format

Share Document